TY - JOUR T1 -哮喘患者过度使用短效β₂受体激动剂与加重和死亡风险增加相关:全球SABINA计划的全国性队列研究JF -欧洲呼吸杂志JO - Eur Respir J DO - 10.1183/13993003.01872-2019 SP - 1901872 AU - Nwaru, Bright I. AU - Ekström, Magnus AU - Hasvold, Pål AU - Wiklund, Fredrik AU - Telg, Gunilla AU - Janson，背景:过度使用短效β2激动剂(SABA)可能提示哮喘控制不良和不良的健康结果。关于SABA(过度)使用对哮喘加重和死亡率的影响、风险因素和当代基于人群的数据很少，这促使全球SABINA (SABA在哮喘中的使用)项目启动。方法结合瑞典国家注册中心的数据，纳入2006-2014年12-45岁、使用≥2种阻塞性肺疾病药物的哮喘患者。SABA过度使用定义为在纳入后的一年基线期内收集2个SABA罐。SABA的使用分为3-5、6-10和11+罐/基线年。Cox回归用于检验SABA使用与加重(住院和/或OCS索赔)和死亡率之间的关系。结果纳入哮喘患者365 324例，平均年龄27.6岁;55%女性)，平均随访85.4个月。约30%过度使用SABA, 21%收集3-5罐，7%收集6-10罐，2%收集11+罐。收集的SABA罐数量增加与加重风险增加相关:3-5 (HR 1.26; [95% CI] 1.24–1.28); 6–10 (1.44; 1.41–1.46); and 11+ canisters (1.77; 1.72–1.83) compared to ≤2 canisters·year−1. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed): 3–5 (HR 1.26; 95% CI 1.14–1.39); 6–10 (1.67; 1.49–1.87); and 11+ canisters (2.35, 2.02–2.72) compared to ≤2 canisters·year−1.Conclusion One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr Nwaru reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Ekström reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Hasvold reports other from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Telg reports personal fees from Employed by AZ, during the conduct of the study.Conflict of interest: Dr Christer Janson[AQ2] Conflict of interest: Dr Wicklund reports other from Statisticon/AstraZeneca, during the conduct of the study. ER -